MEDICAL MARIJUANA DL-,001

Four lesser-valued cannabis stocks showed positive performance on Monday, defying the broader sector's downtrend. These stocks—, , , and —present potential investment opportunities. Positive Performers Among Smaller Cannabis Stocks Medical Marijuana Inc. MJNA, priced at $0.0021, has total assets of $72.775 million but faces financial challenges, including a net income loss of $280.475 million and an EBITDA of -$268.242 million. MJNA maintains a gross profit margin of 79.95%. TILT Holdings TLLTF, trading at $0.035, has total assets of $231.188 million and reported revenue of $165.956 million over the last twelve months. However, with a net income loss of $62.384 million and an EBITDA of -$22.018 million, TILT's profitability is under pressure. Its gross profit margin stands at 9.54%. Trees Corp. CANN, at $0.1 per share, lists total assets of $23.247 million. Despite a negative tangible book value per share and a net income loss of $7.082 million, Trees Corp. maintains a gross profit margin of 25.76%. Trees recently reported its Q1 2024 results, revealing total revenue of $3.686 million and an operating loss of $477,348​. Village Farms International VFF, priced at $1.278, holds total assets of $458.439 million with a current ratio of 2.076. With revenue of $299.024 million, VFF shows resilience despite a net income loss of $28.014 million. Their gross profit margin of 19.87% and a market cap of $138.914 million indicate a potential for recovery. Operational Efficiency Medical Marijuana Inc. demonstrates operational efficiency with a gross profit margin of 79.95%, indicating strong control over production costs despite its financial challenges. This margin suggests that MJNA could be managing effectively its cost of goods sold relative to its revenue. On the other hand, Trees Corp. maintains a gross profit margin of 25.76%, reflecting its ability to generate revenue from its operations. Despite reporting a net income loss of $7.082 million and an operating loss in its recent Q1 2024 results, both companies' operational metrics highlight their potential to sustain business activities and improve financial performance. Comparison To Larger Cannabis Companies When compared to larger cannabis companies, the valuation difference is significant. Curaleaf Holdings CURLF is priced at $5.18, down 8.64%, and AdvisorShares Pure US Cannabis ETF MSOS is at $9.08, down 5.47%. Canopy Growth CGC is at $10.48, down 3.46%, Trulieve Cannabis TCNNF at $11.73, down 6.01%, and Green Thumb Industries GTBIF at $12.59, down 4.08%. Only Aurora Cannabis ACB is up, priced at $7.51, up 1.76%. In contrast to these larger names, the smaller stocks in green today have shown modest gains: MJNA at 4.7619%, TLLTF at 1.4493%, CANN at 11.1111%, and VFF at 1.4286%. Investors may consider these lesser-valued stocks for their potential to navigate a volatile market. Each company's financial metrics and operational efficiencies could offer entry points for those looking to diversify within the cannabis sector.» Mehr auf benzinga.com

AGL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that agilon health, inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit May 20, 2024 10:00 AM EDT | Source: Bronstein, Gewirtz & Grossman, LLC New York, New York--(Newsfile Corp. - May 20, 2024) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against agilon health, inc. ("agilon" or "the Company") (NYSE: AGL) and certain of its officers.Class Definition:This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired agilon securities: (1) between January 9, 2023, and January 4, 2024, both dates inclusive (the "Class Period"); or (2) pursuant to the materials issued in connection with the Company's secondary public offering ("SPO") on or about May 16, 2023. Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/AGL.Case Details:According to the Complaint, agilon, headquartered in Austin, Texas, generates profits from reducing medical expenditures. By partnering primarily with Medicare Advantage ("MA") plans as well as traditional Medicare and commercial managed care organizations, agilon receives a fixed monthly payment from payers for each patient under its care. In return, agilon takes on the responsibility of managing the total cost and quality of care for those patients. This model incentivizes agilon and its contracted physician partners to focus on preventive care and improve health outcomes in order to control costs. If the total cost of caring for patients is less than the fixed payments agilon receives, it realizes a profit. However, if costs exceed the payments, agilon incurs a loss. This aspect of financial risk is inherent in agilon's business model.Having clear visibility into utilization trends over time is critical for agilon. The Company's business model relies on analyzing this data to develop evidence-based care plans and coordinate patient care with its partner physicians. agilon claims to track patient healthcare utilization on an ongoing basis, allowing its teams to actively manage costs and quality of care. The ability to forecast utilization accurately and adjust clinical programs accordingly is key to agilon's goal of reducing expenses in order to produce profits.The Complaint alleges that throughout the Class Period and in the SPO Materials, Defendants misled investors about agilon's medical costs by:(1) touting the Company's purported visibility into utilization trends and medical costs;(2) failing to disclose increased medical costs that agilon had incurred prior to and during the Class Period due to higher utilization of healthcare by MA patients;(3) falsely stating that its incurred-but-not-reported (IBNR) Reserve was adequate;(4) making false and misleading statements about the effectiveness of its business model;(5) issuing overly optimistic financial guidance; and(6) issuing risk disclosures that were materially false and misleading because they characterized adverse facts that had already materialized as mere possibilities.As a result of these materially false and misleading statements and omissions, the Complaint further alleges, agilon stock traded at artificially high prices during the Class Period as investors were conditioned to believe that the Company's medical cost expenses were lower than represented. In May 2023, Defendants took advantage and profited enormously by selling hundreds of millions worth of their agilon stock through the SPO at the inflated price of $21.50 per share.The truth about the higher medical costs that agilon had been facing began to emerge on November 2, 2023, according to the Complaint. On that date, agilon reported lower-than-expected third quarter 2023 results due to increased utilization and medical costs. Defendants also lowered the Company's 2023 full-year revenue outlook and informed investors that agilon had increased its IBNR Reserve to account for prior period medical expenses. These results caught analysts off guard.On this news, agilon's stock price fell $2.23, or 13.2 percent, to close at $14.66 on November 3, 2023.Then, on January 5, 2024, agilon surprised investors again by lowering its 2023 profit forecasts. Specifically, the Company reduced its 2023 Medical Margin and Adjusted EBITDA guidance, citing high-than-expected medical costs. Specifically, agilon reduced its 2023 Medical Margin and Adjusted EBITDA outlooks by more than $110 million and $73 million, respectively.On this news, agilon's stock fell $3.45, or 28.6 percent, to close at $8.63 on January 5, 2024.What's Next?A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/AGL or you may contact Peretz Bronstein, Esq. or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in agilon you have until May 20, 2024, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.There is No Cost to YouWe represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.Why Bronstein, Gewirtz & Grossman:Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.Attorney advertising. Prior results do not guarantee similar outcomes.Contact:Bronstein, Gewirtz & Grossman, LLCPeretz Bronstein or Yael Nathanson332-239-2660 | info@bgandg.comTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/202698 SOURCE: Bronstein, Gewirtz & Grossman, LLC» Mehr auf newsfilecorp.com

SAN DIEGO--(BUSINESS WIRE)--Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), announced today that its network marketing division, Kannaway, has completed an Asset Purchase Agreement with eXfuse, LLC, dba KZ1 a Japan based network marketing company. The KZ1 acquisition will increase the sales force of the Company's Kannaway division in Japan by approximately 1,450 individuals and the Company believes the increased sales force will greatly benefit Kannaway's ramp up in the Japanese market. KZ.» Mehr auf businesswire.com